Shares of Tatva Chintan Pharma Chem Ltd. gained up to 11%, recording another 52-week high, on Wednesday, October 17, after the company reported a good set of numbers for the second quarter.
This is the stock’s biggest single-day gain since July 20, 2026, when it had surged 20%.
The company’s profit after tax (PAT) increased by 116% to ₹21.5 crore from ₹9.9 crore last year, while its revenue increased by 76% to ₹217 crore from ₹123 crore in the year-ago period.
Earnings before interest, taxes, depreciation and amortization (EBITDA) increased 83% to ₹40.7 crore from ₹22 crore and its operating margin expanded to 19% from 18% in the year-ago period.
Tatva Chintan’s EBITDA has been consistently increasing for the last six quarters, from ₹17 crore in the first quarter of FY26, ₹22 crore in the second quarter last year, ₹25 crore and ₹28 crore in the previous fiscal to ₹32.5 crore in the first quarter this fiscal and ₹20.7 crore in the September quarter.
The company said it reported its highest-ever quarterly turnover. It said its newer initiatives in energy storage and agro and pharma intermediates are progressively opening up additional opportunities.
During the September quarter, the company said it witnessed erratic short supplies in some of the solvents. This has led to a price increase of these solvents by 60% to 100%, it said.
The company said that despite having healthy revenue growth in highest margin SDA, the above impact has increased its overall raw material cost. It added that it has also experienced a rampant increase in global freights.
Tatva Chintan said it foresees the revenue trend growth with similar momentum over the next quarters and EBITDA margin.
Shares of Tatva Chintan Pharma gained as much as 11% to hit an intraday high of ₹2,113.6. The stock has now given up most of those gains and is now trading nearly 3% higher at ₹1,955.5. The stock is up 47% so far this year.
Also Read: Piramal Finance shares in focus after Q2 net profit jumps 67%; Margins, asset quality stable